Celcuity (CELC) Interest & Investment Income (2016 - 2026)
Celcuity's (CELC) quarterly Interest & Investment Income came in at $4.4 million in Q4 2025, up 43.97% YoY from $3.1 million in Q4 2024, and up 20.71% on a QoQ basis from $3.6 million in Q3 2025.
Analysis
Celcuity (CELC) Interest & Investment Income (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Interest & Investment Income data on file, last reported at $4.4 million in Q4 2025.
- Quarterly Interest & Investment Income rose 43.97% year-over-year to $4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.3 million (up 4.5% YoY) and the FY2025 annual result came in at $12.3 million, up 4.5% from the prior year.
- Interest & Investment Income grew to $4.4 million in Q4 2025, from $3.6 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $4.4 million in Q4 2025 to a low of $389.0 in Q1 2021.
- A 5-year average of $1.6 million and a median of $1.9 million in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2021 — Interest & Investment Income sank 99.39% — and 2023, when it jumped 22588.22%.
- Tracing CELC's Interest & Investment Income over 5 years: stood at $5459.0 in 2021, then jumped by 13379.78% to $735861.0 in 2022, then surged by 209.58% to $2.3 million in 2023, then soared by 33.97% to $3.1 million in 2024, then surged by 43.97% to $4.4 million in 2025.
- The last three Interest & Investment Income figures came in at $4.4 million (Q4 2025), $3.6 million (Q3 2025), and $1.9 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Celcuity | 5.23 Bn | 5.23 Bn | - | 4.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.15 Mn |
| Dec 31, 2025 | 4.39 Mn |
| Sep 30, 2025 | 3.64 Mn |
| Jun 30, 2025 | 1.95 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 3.05 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 2.82 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | 2.28 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Jun 30, 2023 | 1.78 Mn |
| Mar 31, 2023 | 1.85 Mn |
| Dec 31, 2022 | 735,861.00 |
| Sep 30, 2022 | 287,495.00 |
| Jun 30, 2022 | 95,646.00 |
| Mar 31, 2022 | 8,159.00 |
| Dec 31, 2021 | 5,459.00 |
| Sep 30, 2021 | 5,612.00 |
| Jun 30, 2021 | 1,803.00 |